COMMENTARY

SGLT-2 inhibitors – are they to stay?

Arulmozhi D. Kandasamy

Arulmozhi D. Kandasamy
. Email: arul@discoversys.ca
Online First: October 15, 2016 | Cite this Article
Kandasamy, A. 2016. SGLT-2 inhibitors – are they to stay?. Diabesity 2(4): 26-27. DOI:10.15562/diabesity.2016.35


Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a newer class of Type 2 diabetes medications. The drugs are rapidly growing in popularity. In the period between October 2014
and September 2015, doctors wrote 1.5 million prescriptions for Invokana or Farxiga (dapagliflozin), according to the FDA. They also come in extended formulas and in formulas combined with metformin. These drugs work by preventing the kidneys from reabsorbing sugar and releasing it into the blood. But, what makes these medications so effective, could also contribute to a number of side effects. Beginning in December 2015, the FDA released a number of warnings linking these drugs to a number of side effects, some can be fatal. These range from common ones like yeast infections to more dangerous, rare problems like a link to increased
bladder cancer risk and diabetic ketoacidosis
No Supplementary Material available for this article.
Article Views      : 37
PDF Downloads : 16